Exploiting Emerging Supramolecules as In Vivo Sequestrants to Induce Drug Reversal

Status	Finished
Effective start/end date	3/5/24 → 12/31/24

Funding

Reversal Therapeutics Incorporated: $34,187.00

1 Finished

Alpha2 Noradrenergic Antagonist as a Fentanyl Counter Measure
Bardo, M. (PI), Prisinzano, T. (PI) & Alilain, W. (CoI)
University of Kentucky Neuroscience Research Priority Area
1/1/23 → 12/31/23
Project: Research project